NCT07079410View on ClinicalTrials.gov

Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

October 31, 2029

Conditions
Oral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell CarcinomaResectable Oral and Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab+Cetuximab

Neoadjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week/cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles. Adjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week cycle, a total of 17 cycle) for a total of one year.

Trial Locations (1)

200032

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER